Drugs / HL040XC
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01806324 | Apr → Nov 2012 | hyperlipidemia, hypertensive disorder | HanAll BioPharma Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01541943 | Mar 2012 → Nov 2014 | essential hypertension, hyperlipidemia | HanAll BioPharma Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HL-040XC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01541943 ↗ |
| Route | Oral | “Once daily, administered orally, 8 week” NCT01541943 ↗ |